MK-4884 study for advanced solid tumors
Part of Cancer clinical trials.
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with advanced or locally advanced colorectal, kidney (clear cell type), lung, or bile duct cancer that is confirmed by biopsy or pathology
- Your cancer is measurable on imaging scans using standard RECIST criteria
- Your organs (liver, kidneys, heart) are working well enough to tolerate the study drug
- If you have HIV, it must be well controlled on medications for at least 4 weeks
- If you have hepatitis B or C, you must be on appropriate treatment with undetectable viral load
- You have recovered from any recent major surgery and do not have active serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.
This trial tests an investigational drug called MK-2750 for people with certain advanced cancers that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.